Our mission is to provide first-in-class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), glaucoma, and traumatic brain injury. Our treatment, AXER-204, hopes to rebuild connections between healthy and damaged neurons through the blocking of receptors that naturally inhibit axonal growth. We are currently approaching Phase 2 of testing.